Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.
Ticker SymbolANIK
Company nameAnika Therapeutics Inc
IPO dateMay 16, 1985
CEODr. Cheryl Renee Blanchard, Ph.D.
Number of employees288
Security typeOrdinary Share
Fiscal year-endMay 16
Address32 Wiggins Ave
CityBEDFORD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code01730-2315
Phone17814579000
Websitehttps://anika.com/
Ticker SymbolANIK
IPO dateMay 16, 1985
CEODr. Cheryl Renee Blanchard, Ph.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data